rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene.
|
25359494 |
2015 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The aim of our study was to evaluate the combined effects of MSI, BRAF(V600E) and specific KRAS mutation (Gly → Asp; G12D, Gly → Asp, G13D; Gly → Val; G12V) on prognosis in 404 sporadic and 94 hereditary CRC patients.
|
20162668 |
2010 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer.
|
30568222 |
2019 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
KRAS exon 2 analysis was performed on 2239 CRC and 2.2% harbored the c.34G>T transversion.
|
26056087 |
2015 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Biallelic mutations in MUTYH gene were detected in 3/12 (25%) remaining subjects with polyposis and in 6/90 (6.7%) patients with colorectal cancer (CRC) carrying KRAS p.G12C substitution, but not in 231 early-onset CRC cases negative for KRAS p.G12C allele.
|
29406563 |
2018 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
rs397517040
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We detected a GGT insertion between codons 12 and 13 (c.36_37insGGT;p.G12_G13insG) in a CRC patient.
|
24594115 |
2014 |
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls).
|
29048575 |
2017 |
rs712
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
In conclusion, minor allele of rs3025039, rs3212986, and rs712 polymorphisms increases the risk of CRC in the East Asian population, and heterozygote model of rs731236 polymorphism shows protective effect in the Middle East population.
|
31637880 |
2019 |
rs712
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Comparison of the data from patients with control group showed that polymorphism of rs712 in <i>KRAS</i> gene was protective factor, which was associated with susceptibility for CRC.
|
31156795 |
2019 |
rs712
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25).
|
23975373 |
2014 |
rs7960917
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
rs8720
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma</span> (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |